ATXI
- Avenue Therapeutics, Inc.
()
Overview
Company Summary
Avenue Therapeutics, Inc. (ATXI) is a pharmaceutical company focused on developing and commercializing products for the treatment of acute pain. The company is dedicated to addressing the ongoing opioid crisis and aims to provide alternative and non-opioid options for pain management.
ATXI is primarily focused on the development of intravenous (IV) tramadol, a synthetic opioid-like medication that is administered through infusion. Tramadol has been approved for use in more than 80 countries and has established efficacy in managing moderate to moderately severe pain.
The company's lead product candidate, IV tramadol, is being developed as a non-opioid, non-scheduled, IV alternative for the treatment of postoperative pain. Through ongoing clinical trials and collaborations with leading medical professionals, Avenue Therapeutics aims to demonstrate the safety, efficacy, and potential benefits of IV tramadol for patients recovering from surgeries.
Apart from IV tramadol, Avenue Therapeutics also explores and evaluates other potential pain management therapies, indicating a broader focus on addressing the unmet medical needs associated with acute pain.
In summary, Avenue Therapeutics, Inc. specializes in the development and commercialization of non-opioid therapies, with a primary focus on IV tramadol for the treatment of acute pain. By providing alternatives to traditional opioid medications, the company aims to improve patient outcomes and contribute to the reduction of opioid dependence and abuse.